Sign Out
Posology: Dosage in adults with creatinine clearance (CrCL) > 50 mL/min: Table 2 shows the recommended intravenous dose for adults with estimated creatinine clearance (CrCL) > 50 mL/min (see Precautions and PHARMACOLOGY: Pharmacodynamics under Actions). (See Table 2.)
Click on icon to see table/diagram/imageDosage in paediatric patients with creatinine clearance (CrCL) >50 mL/min/1.73 m2: Table 3 shows the recommended intravenous doses for paediatric patients with estimated creatinine clearance (CrCL) > 50 mL/min/1.73 m2 (see Precautions and PHARMACOLOGY: Pharmacodynamics under Actions). (See Table 3.)
Click on icon to see table/diagram/imageSpecial populations: Elderly: No dosage adjustment is required in elderly patients (see PHARMACOLOGY: Pharmacokinetics under Actions).
Renal impairment: No dosage adjustment is required in patients with mild renal impairment (estimated CrCL > 50 - ≤ 80 mL/min) (see PHARMACOLOGY: Pharmacokinetics under Actions).
Table 4 shows the recommended dose adjustments for adults with estimated CrCL ≤ 50 mL/min (see Precautions and PHARMACOLOGY: Pharmacokinetics under Actions).
Dosage in adults with CrCL ≤ 50 mL/min: See Table 4.
Click on icon to see table/diagram/imageTable 5 and Table 6 show the recommended dose adjustments for paediatric patients with estimated CrCL ≤ 50 mL/min/1.73 m2 according to different age groups (see Precautions and PHARMACOLOGY: Pharmacokinetics under Actions).
Dosage in paediatric patients ≥ 2 years of age with CrCL ≤ 50 mL/min/1.73 m2: See Table 5.
Click on icon to see table/diagram/imageDosage in paediatric patients <2 years of age with CrCl ≤ 50 mL/min/1.73 m2: See Table 6.
Click on icon to see table/diagram/imageThere is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73 m2.
Hepatic impairment: No dosage adjustment is required in patients with hepatic impairment (see PHARMACOLOGY: Pharmacokinetics under Actions).
Paediatric population: The safety and efficacy of Zavicefta in paediatric patients < 3 months old have not been established. No data are available.
Method of administration: Intravenous use.
Zavicefta is administered by intravenous infusion over 120 minutes in an appropriate infusion volume (see Special precautions for disposal and other handling under Cautions for Usage).
For instructions on reconstitution and dilution of the medicinal product before administration see Special precautions for disposal and other handling under Cautions for Usage.
Continue with Google